Growth inhibition of prostate cancer cells by epigallocatechin gallate in the presence of Cu2+.

J Agric Food Chem

Department of Tea Sciences, Zhejiang University, Hangzhou 310029, Peoples Republic of China.

Published: February 2004

Green tea is an effective chemopreventive agent to human prostate cancer adenoma (PCA). Epigallocatechin gallate (EGCG) inhibited the growth of PCA cells and induced apoptosis. Cu(2+) is a trace element necessary to our health. Many studies proved that bioactivity of EGCG is altered in the presence of Cu(2+). We investigated the effects of EGCG on PCA cells in the presence of Cu(2+). Also, we explored potential mechanisms via measurement of the relative chemiluminescence of growth medium for PCA cells. Chemiluminscence can be an indication of free radicals. Our test results showed that the addition of EGCG and Cu(2+) to the growth medium decreased the relative viability of androgen-sensitive and androgen-insensitive human prostate cancer cells. However, the effects of EGCG on PCA cells depended on (1) the relative concentrations of added EGCG and Cu(2+) and (2) their order of addition. Our results indicated that few free radicals may be generated in vitro. If so, free radicals generated intracellularly may be a major factor behind apoptosis and growth inhibition observed in the PCA cells. Thus, EGCG might exert its effects intracellularly.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jf035057uDOI Listing

Publication Analysis

Top Keywords

pca cells
20
prostate cancer
12
presence cu2+
12
free radicals
12
growth inhibition
8
cancer cells
8
epigallocatechin gallate
8
human prostate
8
effects egcg
8
egcg pca
8

Similar Publications

Cancer is one of the most fatal diseases threatening public health globally, and tumor metastasis causes greater than 90 % of cancer-associated deaths, presenting huge challenges for detection and efficient treatment of various human cancers. Cancer stem cells (CSCs) are a rare population of cancer cells and increasing evidences indicated CSCs are the driving force of tumor metastasis. In this study, a p-AuNSs-assisted single-cell Raman spectra has been established, to extract and amplify of CSCs fingerprints with single cell sensitivity.

View Article and Find Full Text PDF

Background: Chromosomal instability (CIN), a hallmark of cancer, is commonly linked to poor prognosis in high-grade prostate cancer (PCa). Paradoxically, excessively high levels of CIN may impair cancer cell viability. Consequently, understanding how tumours adapt to CIN is critical for identifying novel therapeutic targets.

View Article and Find Full Text PDF

Background: Prostate cancer (PCa) is a multifactorial and heterogeneous disease, ranking among the most prevalent malignancies in men. In 2020, there were 1,414,259 new cases of PCa worldwide, accounting for 7.3% of all malignant tumors.

View Article and Find Full Text PDF

Regulator of G protein signaling 1 (RGS1) is known to be highly expressed in various tumors, but its specific effects and regulatory mechanism in ovarian cancer (OC) progression are not well understood. To delve into the tumor biology, a predictive risk model for OC was developed, incorporating RGS1, PRKG2, CD24, and ABCB1, with RGS1 exhibiting the strongest correlation. The model's reliability and validity were confirmed through Kaplan-Meier analysis, receiver operating characteristic (ROC) curve, and principal component analysis (PCA).

View Article and Find Full Text PDF

Background: Caffeic acid (CA), a dietary compound, has been studied for its potential impact on inhibiting prostate cancer (PCa) growth. PCa is often associated with heightened expression of glyoxalase-1 (Glo-1), making it a target for potential therapeutic interventions. CA's mechanisms in suppressing Glo-1 expression and its effects on PCa cell proliferation are areas of interest for understanding its potential as an anticancer agent.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!